Cargando…
Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains contr...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704936/ https://www.ncbi.nlm.nih.gov/pubmed/36451458 http://dx.doi.org/10.1097/MD.0000000000031962 |
_version_ | 1784840169206054912 |
---|---|
author | Elsebaey, Mohamed A. Elbedewy, Tamer A. Elashry, Heba Elrefaey, Waleed Elshweikh, Samah A. Elhadidy, Ahmed A. Shalaby, Neveen A. Elsokkary, Assem Mohamed Elashtokhy, Hossam Eldin A. Abo-Amer, Yousry Esam-Eldin Abo-Elfetoh, Ashraf Rafat Hassanien, Sharaf Elsayed Ali Fouad, Amina Abdellatif, Raghda Samir Ismail, Amro Abdelaziz Mohammed |
author_facet | Elsebaey, Mohamed A. Elbedewy, Tamer A. Elashry, Heba Elrefaey, Waleed Elshweikh, Samah A. Elhadidy, Ahmed A. Shalaby, Neveen A. Elsokkary, Assem Mohamed Elashtokhy, Hossam Eldin A. Abo-Amer, Yousry Esam-Eldin Abo-Elfetoh, Ashraf Rafat Hassanien, Sharaf Elsayed Ali Fouad, Amina Abdellatif, Raghda Samir Ismail, Amro Abdelaziz Mohammed |
author_sort | Elsebaey, Mohamed A. |
collection | PubMed |
description | Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains controversial. The aim of the study was to determine the incidence of HBVr and HBV-related hepatitis in resolved HBV patients who received immunosuppressive therapy with or without antiviral prophylaxis. This retrospective study included 64 patients with resolved HBV infection who received different regimens of immunosuppressive medications, with moderate risk of HBVr, for variable underlying diseases. Patients who had chronic HBV infection or other viral infections were excluded. Patients who received B-cell depleting therapies were ruled out. They were divided into 2 groups: group 1 included 31 patients who received immunosuppressive therapy without antiviral prophylaxis, and group 2 included 33 patients who received antiviral prophylaxis (entecavir) within 2 weeks of commencing the immunosuppressive therapy. HBVr, HBV-related hepatitis, and HBV-unrelated hepatitis were assessed along a 1-year duration. The overall HBVr incidence was 1.56% (1/64). This patient who had HBVr was seen in group 1. There were no significant differences between the 2 groups regarding the incidence of HBVr, HBV-related hepatitis, HBV-unrelated hepatitis, and immunosuppressive therapy interruption along a 1-year duration. Based on this retrospective study, close monitoring was equal to antiviral prophylaxis regarding the outcome of resolved HBV patients who received moderate risk immunosuppressive therapy. HBV treatment should commence once HBVr is confirmed. |
format | Online Article Text |
id | pubmed-9704936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97049362022-11-29 Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation Elsebaey, Mohamed A. Elbedewy, Tamer A. Elashry, Heba Elrefaey, Waleed Elshweikh, Samah A. Elhadidy, Ahmed A. Shalaby, Neveen A. Elsokkary, Assem Mohamed Elashtokhy, Hossam Eldin A. Abo-Amer, Yousry Esam-Eldin Abo-Elfetoh, Ashraf Rafat Hassanien, Sharaf Elsayed Ali Fouad, Amina Abdellatif, Raghda Samir Ismail, Amro Abdelaziz Mohammed Medicine (Baltimore) 4500 Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains controversial. The aim of the study was to determine the incidence of HBVr and HBV-related hepatitis in resolved HBV patients who received immunosuppressive therapy with or without antiviral prophylaxis. This retrospective study included 64 patients with resolved HBV infection who received different regimens of immunosuppressive medications, with moderate risk of HBVr, for variable underlying diseases. Patients who had chronic HBV infection or other viral infections were excluded. Patients who received B-cell depleting therapies were ruled out. They were divided into 2 groups: group 1 included 31 patients who received immunosuppressive therapy without antiviral prophylaxis, and group 2 included 33 patients who received antiviral prophylaxis (entecavir) within 2 weeks of commencing the immunosuppressive therapy. HBVr, HBV-related hepatitis, and HBV-unrelated hepatitis were assessed along a 1-year duration. The overall HBVr incidence was 1.56% (1/64). This patient who had HBVr was seen in group 1. There were no significant differences between the 2 groups regarding the incidence of HBVr, HBV-related hepatitis, HBV-unrelated hepatitis, and immunosuppressive therapy interruption along a 1-year duration. Based on this retrospective study, close monitoring was equal to antiviral prophylaxis regarding the outcome of resolved HBV patients who received moderate risk immunosuppressive therapy. HBV treatment should commence once HBVr is confirmed. Lippincott Williams & Wilkins 2022-11-25 /pmc/articles/PMC9704936/ /pubmed/36451458 http://dx.doi.org/10.1097/MD.0000000000031962 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 4500 Elsebaey, Mohamed A. Elbedewy, Tamer A. Elashry, Heba Elrefaey, Waleed Elshweikh, Samah A. Elhadidy, Ahmed A. Shalaby, Neveen A. Elsokkary, Assem Mohamed Elashtokhy, Hossam Eldin A. Abo-Amer, Yousry Esam-Eldin Abo-Elfetoh, Ashraf Rafat Hassanien, Sharaf Elsayed Ali Fouad, Amina Abdellatif, Raghda Samir Ismail, Amro Abdelaziz Mohammed Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation |
title | Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation |
title_full | Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation |
title_fullStr | Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation |
title_full_unstemmed | Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation |
title_short | Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation |
title_sort | resolved hepatitis b infection in patients receiving immunosuppressive therapy: monitor versus prophylaxis against viral reactivation |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704936/ https://www.ncbi.nlm.nih.gov/pubmed/36451458 http://dx.doi.org/10.1097/MD.0000000000031962 |
work_keys_str_mv | AT elsebaeymohameda resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT elbedewytamera resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT elashryheba resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT elrefaeywaleed resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT elshweikhsamaha resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT elhadidyahmeda resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT shalabyneveena resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT elsokkaryassemmohamed resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT elashtokhyhossameldina resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT aboameryousryesameldin resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT aboelfetohashrafrafat resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT hassaniensharafelsayedali resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT fouadamina resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT abdellatifraghdasamir resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation AT ismailamroabdelazizmohammed resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation |